fingolimod hydrochloride has been researched along with organophosphonates in 11 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (organophosphonates) | Trials (organophosphonates) | Recent Studies (post-2010) (organophosphonates) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 9,968 | 880 | 3,596 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bergstrom, J; Card, D; Hajdu, R; Hale, J; Keohane, C; Lynch, CL; Mandala, S; Milligan, J; Parsons, W; Quackenbush, E; Rosen, H; Rosenbach, M; Rupprecht, K; Shei, GJ; Thornton, R; Xie, J | 1 |
| Bittman, R; Liu, J; Lu, X; Shuyu, E; Sun, C; Tigyi, G; Valentine, WJ | 1 |
| Bittman, R; Camp, SM; Chiang, ET; Dudek, SM; Garcia, JG; Harbeck, M; Lu, X; Mirzapoiazova, T; Moreno-Vinasco, L; Natarajan, V; Roe, M; Sammani, S; Sun, C | 1 |
| Bittman, R; Lim, KG; Long, J; Loveridge, C; Pitson, SM; Pyne, NJ; Pyne, S; Tigyi, G; Tonelli, F | 1 |
| Bittman, R; Pyne, NJ; Pyne, S | 1 |
| Bieberich, E; Bryant, L; Chen, C; Chen, Z; Cuzzocrea, S; Doyle, T; Esposito, E; Janes, K; Kamocki, K; Li, C; Little, JW; Neumann, WL; Nicol, G; Obeid, L; Petrache, I; Salvemini, D; Snider, A | 1 |
| Bittman, R; Dudek, SM; Garcia, JG; Wang, L | 1 |
| Guerrero, M; Kays, J; Li, C; Li, JN; Nicol, GD | 1 |
| Donahue, RR; Doolen, S; Grachen, CM; Iannitti, T; Shaw, BC; Taylor, BK | 1 |
| Fu, J; Gao, F; Gao, Y; Li, Y; Meng, F; Yang, C | 1 |
| Bandela, M; Belvitch, P; Brown, ME; Chen, J; Dudek, SM; Garcia, JGN; Letsiou, E; Meliton, LN; Wang, H; Wang, L | 1 |
1 review(s) available for fingolimod hydrochloride and organophosphonates
| Article | Year |
|---|---|
Sphingosine kinase inhibitors and cancer: seeking the golden sword of Hercules.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Cell Division; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Fingolimod Hydrochloride; Humans; Lysophospholipids; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Organophosphonates; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Sphingosine; Vinyl Compounds | 2011 |
10 other study(ies) available for fingolimod hydrochloride and organophosphonates
| Article | Year |
|---|---|
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.
Topics: Animals; B-Lymphocytes; Binding, Competitive; Calcium; CHO Cells; Cricetinae; Cyclic AMP; Fingolimod Hydrochloride; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Immunosuppressive Agents; Ligands; Lymph Nodes; Lymphocyte Count; Lymphopenia; Lysophospholipids; Mice; Organophosphates; Organophosphonates; Phosphorylation; Propylene Glycols; Rats; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, Lysophospholipid; Sphingosine; Spleen; Stereoisomerism; T-Lymphocytes | 2002 |
Chiral vinylphosphonate and phosphonate analogues of the immunosuppressive agent FTY720.
Topics: Animals; Cells, Cultured; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Intestinal Mucosa; Molecular Structure; Organophosphonates; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Stereoisomerism; Vinyl Compounds | 2009 |
Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro.
Topics: Animals; Capillary Permeability; Cell Line; Fingolimod Hydrochloride; Humans; Inflammation Mediators; Lung; Mice; Mice, Inbred C57BL; Organophosphonates; Propylene Glycols; Pulmonary Artery; Sphingosine | 2009 |
FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.
Topics: Androgens; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fingolimod Hydrochloride; Humans; Male; Muscle, Smooth, Vascular; Organophosphonates; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pulmonary Artery; Sphingosine; Stereoisomerism; Vinyl Compounds | 2010 |
The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.
Topics: Anilides; Animals; Antineoplastic Agents, Phytogenic; Cytokines; Enzyme Activation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Indans; Lysophospholipids; Male; Neuralgia; Organophosphonates; Oxadiazoles; Paclitaxel; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; Thiazoles; Thiophenes | 2014 |
Junctional complex and focal adhesion rearrangement mediates pulmonary endothelial barrier enhancement by FTY720 S-phosphonate.
Topics: Acute Lung Injury; Antigens, CD; Antigens, Nuclear; Cadherins; Endothelial Cells; Fingolimod Hydrochloride; Focal Adhesion Protein-Tyrosine Kinases; Focal Adhesions; Humans; Immunosuppressive Agents; Lung; Lysophospholipids; Microscopy, Fluorescence; Nerve Tissue Proteins; Organophosphonates; Proto-Oncogene Proteins c-akt; rac1 GTP-Binding Protein; Receptors, Lysosphingolipid; RNA, Small Interfering; Sphingosine; Transcription Factors; Zonula Occludens-1 Protein | 2015 |
Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and/or 3.
Topics: Action Potentials; Anilides; Animals; Cells, Cultured; Dinoprostone; Enzyme Inhibitors; Fingolimod Hydrochloride; Ganglia, Spinal; Gene Expression Regulation; Immunosuppressive Agents; Lysophospholipids; Mice; Mice, Inbred C57BL; Organophosphonates; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; RNA, Small Interfering; Sensory Receptor Cells; Sphingosine; Sphingosine-1-Phosphate Receptors; Thiazolidines | 2015 |
Fingolimod reduces neuropathic pain behaviors in a mouse model of multiple sclerosis by a sphingosine-1 phosphate receptor 1-dependent inhibition of central sensitization in the dorsal horn.
Topics: Anilides; Animals; Central Nervous System Sensitization; Disease Models, Animal; eIF-2 Kinase; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Mice; Mice, Inbred C57BL; Motor Activity; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Neuralgia; Organophosphonates; Oxadiazoles; Pain Threshold; Peptide Fragments; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; Spinal Cord; Spinal Nerve Roots; Subcellular Fractions; Thiophenes | 2018 |
The Sphingosine 1-Phosphate Analogue FTY720 Alleviates Seizure-induced Overexpression of P-Glycoprotein in Rat Hippocampus.
Topics: Anilides; Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclooxygenase 2; Disease Models, Animal; Drug Resistant Epilepsy; Fingolimod Hydrochloride; Hippocampus; Humans; Immunosuppressive Agents; Injections, Intraperitoneal; Lysophospholipids; Male; Organophosphonates; Phenytoin; Pilocarpine; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Up-Regulation | 2018 |
MRSA-induced endothelial permeability and acute lung injury are attenuated by FTY720 S-phosphonate.
Topics: Acute Lung Injury; Animals; Antigens, CD; Cadherins; Cell Membrane Permeability; Cytoprotection; Cytoskeleton; Endothelial Cells; Enzyme Activation; Fingolimod Hydrochloride; Humans; Inflammation; Methicillin-Resistant Staphylococcus aureus; Mice; Myosin Light Chains; Organophosphonates; Phosphorylation; rhoA GTP-Binding Protein; Signal Transduction | 2022 |